Synthesis and antitumor evaluation of neolaxiflorin B inspired compounds
Received 15 March 2019
Accepted for publication 9 July 2019
Published 23 August 2019 Volume 2019:13 Pages 3021—3028
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Sukesh Voruganti
Jing-Ping Liu,1 Ye-Zhi Xiao,1 Yu Hu,1 Xiao-Nian Li,2 Ming-Jiang Wu,3 Yong Zhao,1 Yan Zhao,1 Ze-Jin Ma,1 Jing Shen1
1Department of Chemistry, Yunnan Normal University, Kunming 650092, People’s Republic of China; 2State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Kunming 650201, People’s Republic of China; 3Criminal Science and Technology Key Lab of Yunnan Police College, Kunming 650223, People’s Republic of China
Correspondence: Jing-Ping Liu; Jing Shen
Department of Chemistry, Yunnan Normal University, No. 298, 121st Street, Yunnan, Kunming 650092, People’s Republic of China
Tel/Fax +86 8 716 513 2144
Background: Neolaxiflorin B is derived from ent-kaurane like laxiflorin J and eriocalyxin B with a relatively low potency as an antitumor agent. During preliminary structure–activity relationship studies, the α,β-unsaturated ketone (enone) system is an important active group.
Methods: Seven neolaxiflorin B derivatives containing α,β-unsaturated ketone moieties were synthesized. In vitro, activity was evaluated against three human tumor cell lines and a rat myogenic cell line (HepG2, NSCLC-H292, SNU-1040, and L6, respectively) by MTT assay.
Results: Compound 15 appeared a promising antitumor lead due to its cytotoxic potency and relatively high selectivity, with an SI value of 13.14. Flow cytometry analysis was conducted to show that NSCLC-H292 cells were blocked in the G0/G1 phase in the presence of compound 15, thus inhibiting the proliferation of tumor cells.
Conclusion: This study has revealed that compound 15 is a promising antitumor lead due to the cytotoxic potencies and the high selectivity it displayed when compared to natural counterparts.
Keywords: neolaxiflorin B inspired compounds, unsaturated ketone, antitumor activity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]